In 2003 the GlaxoSmithKline African Malaria Partnership disbursed the first community development grants in a $1.5 million three-year initiative to combat malaria. The aim of this partnership is to develop effective malaria control behaviors in African communities and nearly two million people will be reached through the initiative's programs in eight African countries. Funded activities include developing a malaria education module as part of Freedom From Hunger's ‘Credit with Education' program that is expected to reach 500,000 people in Benin, Burkina Faso, Ghana, Mali and Togo; in the Sudan, advocacy for effective prevention and treatment, creation of malaria-control networks and partnerships, and public education in partnership with Plan International; and a Ugandan program in partnership with AMREF, Africare, Uganda Red Cross, CDFU and the Ugandan government for mothers and children under five years of age that uses community-based interventions, advocacy and multi-media approaches to promote prevention, detection and treatment. GlaxoSmithKline is also providing all of its antimalarial medicines at not for profit prices in all the Least Developed Countries and all the countries of sub-Saharan Africa.